Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|May 7, 2021
- Ophthalmology Times: May 2021
- Volume 46
- Issue 8
Reading glasses denial
Author(s)Jon Carter
Check out the latest cartoon!
Advertisement
Articles in this issue
over 5 years ago
Method of predicting glaucoma conversion proves to be fasterover 5 years ago
Dropless glaucoma treatment an elusive path to ease burdenover 5 years ago
MIGS and cataract surgery option offers positive resultsover 5 years ago
Investigators start pivotal subretinal gene therapy trialover 5 years ago
Examining stability of aspheric IOL in cataract patientsover 5 years ago
The use of MIGS trends and patterns in the USover 5 years ago
Snapshot: Managing endogenous endophthalmitis in patientsover 5 years ago
Retinal nonperfusion, leakage linked with center-involved DMEover 5 years ago
New options are on horizon for presbyopia-correcting dropsAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
3
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
4
Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery
5